KZIA

Kazia Therapeuti

• NASDAQ·3h ago

  Leerink Partners Initiates Coverage of Kazia Therapeutics Limited - Depositary Receipt with Outperform Rating

• Benzinga·4h ago

  Leerink Partners Initiates Coverage On Kazia Therapeutics with Outperform Rating, Announces Price Target of $30

• TipRanks·5h ago

  Leerink bullish on Kazia Therapeutics, initiates with an Outperform

• TipRanks·6h ago

  Kazia Therapeutics initiated with an Outperform at Leerink

• TipRanks·21h ago

  Kazia Therapeutics management to meet with BTIG

• TipRanks·10/01 14:30

  Analysts Offer Insights on Healthcare Companies: United Therapeutics (UTHR), Kazia Therapeutics (KZIA) and FocalTherics (FOCL)

• TipRanks·09/23 09:55

  Analyst Reiterates Buy on Kazia Therapeutics, Maintaining $40 Price Target as Paxalisib Advances into Rare Epilepsy Trial

• TipRanks·09/22 12:27

  Kazia Therapeutics Gains $2 Million Milestone as Sovargen Doses First Paxalisib Patient in Rare Epilepsy Trial

• TipRanks·09/22 11:40

  Kazia Therapeutics licensee doses first patient in Phase 1b/2a paxalisib trial

• Benzinga·09/22 11:33

  Kazia Therapeutics Announces Sovargen Doses First Participant In Phase 1b/2a Clinical Study Of Paxalisib To Treat Epilepsies

• TipRanks·09/18 20:44

  Kazia Therapeutics Switches ADR Depositary to JPMorgan as ADSs Remain on Nasdaq

• Dow Jones·09/10 13:23

  Kazia Therapeutics Price Target Maintained With a $40.00/Share by BTIG

• Benzinga·09/10 13:13

  BTIG Reiterates Buy on Kazia Therapeutics, Maintains $40 Price Target

• NASDAQ·09/09 14:20

  Kazia Doses First Patient In Phase 2 PNOC035 Study Of Paxalisib In Pediatric Brain Cancer; Stock Up